Literature DB >> 28652092

Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer.

A Patrikidou1, M Uccello2, A Tree1, C Parker2, G Attard1, R Eeles3, V Khoo3, N van As4, R Huddart1, D Dearnaley1, A Reid2.   

Abstract

Entities:  

Year:  2017        PMID: 28652092     DOI: 10.1016/j.clon.2017.06.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  1 in total

1.  Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Authors:  Marie-Rose B S Crombag; Aurelia H M de Vries Schultink; Jacobine G C van Doremalen; Hans-Martin Otten; Andries M Bergman; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.